Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate

Archives of Andrology

Volumn 53, Issue 1, 2007, Pages 17-20

  Ravish, I R ^a   Nerli, R B ^a   Amarkhed, S S ^a  

^a KLES DR PRABHAKAR KORE HOSPITAL MEDICAL RESEARCH CENTRE   (India)

Author keywords

BPH; Dutasteride; Finasteride; LUTS; Prostate

Indexed keywords

DUTASTERIDE; FINASTERIDE; ISOENZYME; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE TYPE 1; STEROID 5ALPHA REDUCTASE TYPE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOWER URINARY TRACT SYMPTOM; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

AZASTEROIDS; DIURESIS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 33847156755     PISSN: 01485016     EISSN: 15210375     Source Type: Journal    
DOI: 10.1080/01485010600888953     Document Type: Article

References (21)

1. Andersen JT, Nickel JC, Marshal VR (1997): Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49:839-845.
2. Boyle PP, Siami P, Wachs BH (2002): Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment. J Urol 167:372-378.
3. Boyle P, Roehrborn C, Marks L (2003): Early use of dutasteride arrests prostate growth, improves clinical parameters and prevents complications in men with benign prostatic hyperplasia. J Urol 169:477-482.
4. Brooks JR, Berman C, Garnes D (1986): Prostatic effects induced in dogs by chronic or acute oral administration of 5α-reductase inhibitors. Prostate 9:65-69.
5. Clark RV, Hermann DJ, Gabriel H (?): Almost complete suppression of dihydrotestosterone in men with BPH by GII98745, a novel, dual 5-alpha-reductase inhibitor. North Carolina: GlaxoSmith Kline (unpublished data: 2000 March).
6. Evans HC, Goa KL (2003): Dutasteride. Drugs Aging 20:905-916.
7. Finasteride Study Group (1993): Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22:291-299.
8. Gisleskog PO, Hermann D, Hammarlund-Udenaes M (1998): A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GII98745 and finasteride. Clin Pharmacol Ther 64:636-647.
9. Gormley GJ, Stoner E, et al. (1992): The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327:1185-1191.
10. Griffin JE, Wilson JD (1985): Disorders of the testes and male reproductive tract. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW, (Eds). Philadelphia: WB Saunders, p 259.
11. Hermann DJ, Wilson TH, Morill BB (1997): A 28-day evaluation of GII98745, a potent dual 5-alpha reductase inhibitor, in BPH patients. J Urol 157(4suppl):315-319.
12. Jenkins EP, Andersson S, et al. (1992): Genetic and pharmacological evidence for more than one human steroid 5alfa-reductase. J Clin Invest 89:293-300.
13. Liang T, Heiss CE, Cheung AH (1982): 4-Azasteroid-5α-reductase inhibitors without affinity for the androgen receptor. J Biochem 259:734.
14. O'Leary MP, Roehrborn C, Andriole G (2003): Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 92:262-266.
15. Rittimaster RS, Stoner E, Thompson DL (1989): Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 10:259.
16. Roehrborn CG, Boyle P, Nickel JC (2002): Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. ARIA 3001, ARIA 3002 and ARIA 3003 study investigators. Urology 60:434-441.
17. Roehrborn C, Ramsdell J, Siami P (2002): Prostate volume at baseline predicts the margin of therapeutic response with the 5α-reductase inhibitor, dutasteride. J Urol 167 suppl:373-379.
18. Silver RI, Wiley EI, et al. (1994): Cell type specific expression of steroid 5alfa-reductase 2. J Urol 152:438-442.
19. Thigpen AE, Davis DL, et al. (1992): Molecular genetics of steroid 5alfa-reductase 2 deficiency. J Clin Invest 90:799-809.
20. Thigpen AE, Silver RI, et al. (1993): Tissue distribution and ontogeny of steroid 5alfa-reductase isoenzyme expression. J Clin Invest 92:903-910.
21. Vermeulen A, Giagulli VA, Schepper PD (1989): Hormonal effects of an orally active 4-azasteroid inhibitor or 5α-reductase in humans. Prostate 14:45.